Tenon Medical, Inc. reported its financial results for the second quarter ended June 30, 2025, on August 13, 2025. Revenue for Q2 2025 was $564,000, marking a 37% decrease from $901,000 in Q2 2024, primarily due to lower procedure volumes and strategic shifts related to the impending SiVantage acquisition.
Gross profit for the quarter was $245,000, resulting in a gross margin of 43%, down from 52% in Q2 2024. However, operating expenses saw a significant improvement, totaling $3.1 million, a 29% reduction year-over-year from $4.3 million, driven by disciplined spending and reduced stock-based compensation.
The net loss for Q2 2025 improved to $2.8 million, or $0.36 per share, compared to a net loss of $3.8 million, or $0.816 per share, in Q2 2024. The company ended the quarter with $7.8 million in cash and cash equivalents and no outstanding debt. Management highlighted the recently completed strategic acquisition of SiVantage, the full commercial launch of Catamaran SE in the coming weeks, and initial alpha surgeries for the Symmetry Plus system expected in Q4 2025 as key growth drivers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.